HomeBIOTECHNOLOGY
BIOTECHNOLOGY
Medical Device News Magazine reports breaking biotechnology news in addition to medical device news.
New Data Show Genentech’s Subcutaneously Administered Crovalimab Achieved Disease Control and Was Well-Tolerated in People With Paroxysmal Nocturnal Hemoglobinuria (PNH)
“With the option for subcutaneous self-administration, crovalimab could help meet the lifelong needs of people living with PNH and their caregivers,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Genetech Global Product Development. “Data from the COMMODORE studies will be submitted to regulatory authorities around the world.”
DxVx, Won the Governmental Project to Develop Diagnostic Sensor Kit for Adult Diseases
In this project, which will be carried out over three years with a total budget of about $3.6 million($2.8 million in government support), Dx&Vx will lead the development as a lead company.
Hememics Biotechnologies, Inc. and General Graphene Corporation Cement Strategic Partnership for Large-Scale Production of Graphene-Based Biosensors
In the past nine months alone, Hememics in conjunction with General Graphene has manufactured more than 100,000 graphene biosensors. Using its patented desiccation technology for detection biology, Hememics has functionalized and tested these biosensors through numerous molecular and antigen tests to detect SEB and ricin at consistent sensitivities in the low picomolar range and get results within 5 minutes.
Telix Opens European Radiopharmaceutical Production Facility
Located in the heart of Belgium’s ‘Radiopharma Valley’, the 2,800 square metre facility is one of Europe’s largest radiopharmaceutical production facilities. It will serve as the primary manufacturing site for radioisotopes and commercial and clinical products for patients in the Europe Middle East and Africa (EMEA) region and beyond advises Telix.
PathPresenter Empowers Biorepositories to Share Pathology Imaging Data for Biomedical Research
The scalable and secure cloud-based platform makes the imaging data easily available to researchers and provides smart tools to maximize collaborative research for the ultimate benefit of patients and donors. By adopting the PathPresenter platform, biorepositories and organizations have a unique opportunity to generate a return on investment for their digital pathology infrastructure.
Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses Against Head and Neck Carcinoma at...
TG4050, the first individualized therapeutic vaccine based on the myvac platform, TG4001 for the treatment of HPV-positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO viral backbone.
Blueprint Medicines Highlights Clinical Progress Across Precision Oncology Pipeline at 2023 ASCO Annual Meeting
"At ASCO, we are reporting early clinical data for three therapeutic candidates highlighting the breadth of our pipeline, which lays the foundation for our next wave of precision therapy programs to tackle significant medical challenges," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. "Together, these presentations reflect how we are developing differentiated, highly selective therapies against promising disease targets, and demonstrate strong execution in advancing potential treatment options for large patient populations, including HR+/HER2- breast cancer and EGFR-mutant lung cancer. The datasets represent a diversity of fundamental value drivers in our clinical portfolio, which create opportunities to substantially expand our patient impact and highlight our ambition to deliver many more transformational medicines to patients in the future."
Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting
The company updated the Phase 1b efficacy and safety results of IBI939 (anti-TIGIT antibody) combined with sintilimab (anti-PD-1 antibody) in previously untreated PD-L1-selected NSCLC without sensitizing mutations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
Pangaea Data Awarded Strategic Partnership by Mersey Care NHS Foundation Trust and the University of Liverpool’s Mental Health Research for Innovation Centre (M-RIC)
Dr. Vibhor Gupta, Founder and Director at Pangaea, said: “We are excited to partner with Mersey Care NHS Foundation Trusts and the University of Liverpool’s Mental Health Research for Innovation Centre (M-RIC). The application of Pangaea’s product in the context of mental health conditions is critical, for both patients and clinicians, to support preventative health and precision medicine.”
